lossoffunct
mutat
gene
encod
ubiquitin
ligas
parkin
frequent
caus
recess
parkinson
diseas
pd
parkin
transloc
cytosol
depolar
mitochondria
ubiquitin
outer
mitochondri
membran
protein
induc
select
autophagi
damag
mitochondria
mitophagi
show
ubiquitinspecif
proteas
deubiquitin
enzym
dub
wide
express
brain
organ
oppos
parkinmedi
mitophagi
panel
dub
catalyt
inact
version
moreov
knockdown
rescu
mitophagi
defect
pd
patient
fibroblast
mutat
decreas
parkin
level
affect
ubiquitin
statu
parkin
parkin
transloc
mitochondria
counteract
parkinmedi
mitochondri
ubiquitin
knockdown
dub
closest
homolog
drosophila
larg
rescu
mitochondri
behavior
defect
parkin
rnai
fli
data
identifi
antagonist
parkin
suggest
inhibit
could
therapeut
strategi
pd
case
caus
reduc
parkin
level
parkinson
diseas
pd
disord
substantia
nigra
dopaminerg
neuron
sever
neuron
subpopul
gradual
degener
caus
wide
rang
disabl
motor
nonmotor
problem
lifetim
risk
develop
pd
subset
pd
case
famili
mutat
gene
encod
cytosol
ubiquitin
ligas
parkin
frequent
caus
autosom
recess
pd
probabl
lossoffunct
mechan
addit
role
famili
pd
parkin
defici
may
also
contribut
pathogenesi
sporad
pd
parkin
progress
inactiv
age
human
brain
result
posttransl
modif
phenotyp
parkinnul
fli
mice
fibroblast
pd
patient
mutat
primarili
consist
mitochondri
abnorm
long
puzzl
given
cytosol
local
parkin
howev
recent
work
varieti
experiment
model
shown
parkin
transloc
cytosol
depolar
mitochondria
ubiquitin
larg
number
mitochondri
outer
membran
mom
protein
thu
trigger
select
macroautophag
remov
damag
mitochondria
mitophagi
action
ubiquitin
ligas
counteract
deubiquitin
enzym
dub
catalyz
remov
ubiquitin
substrat
human
proteom
contain
function
dub
belong
subclass
largest
correspond
address
depart
neurolog
univers
hospit
leuven
herestraat
leuven
belgium
tel
fax
email
wimvandenbergh
uzleuvenb
ubiquitinspecif
proteas
usp
famili
whether
dub
antagon
enzymat
effect
parkin
current
unknown
identif
parkin
antagonist
dub
could
lead
attract
new
therapeut
strategi
pd
name
inhibit
dub
identifi
dub
counteract
parkinmedi
mitochondri
ubiquitin
mitophagi
recent
use
tandem
affin
purif
coupl
mass
spectrometri
search
parkininteract
protein
cell
express
flagparkin
among
parkinassoci
protein
identifi
two
dub
absent
neg
control
condit
supplementari
materi
tabl
two
close
relat
usp
ident
similar
amino
acid
level
coimmunoprecipit
western
blot
confirm
interact
overexpress
parkin
supplementari
materi
fig
unabl
coimmunoprecipit
endogen
parkin
cell
assum
bind
parkin
weak
detect
endogen
parkin
express
level
ask
function
interact
parkin
assay
parkin
function
employ
wide
use
hela
cell
model
parkinmedi
mitophagi
hela
cell
express
endogen
parkin
transfect
parkin
treat
mitochondri
uncoupl
carbonyl
cyanid
mchlorophenylhydrazon
cccp
valinomycin
h
depolar
mitochondria
elimin
autophagi
parkindepend
manner
search
effect
dub
parkinmedi
mitophagi
hela
cell
transfect
parkin
alon
cotransfect
parkin
panel
dub
present
initi
proteom
screen
closest
homolog
sequenc
ident
similar
amino
acid
level
dub
anchor
mom
face
cytosol
catalyt
domain
dub
genet
link
pd
suggest
dub
report
bind
parkin
dub
involv
nfkb
pathway
parkin
also
implic
fig
interestingli
strongli
inhibit
parkinmedi
human
molecular
genet
vol
mitophagi
dub
effect
fig
b
western
blot
show
express
level
transfect
least
high
rule
stronger
express
reason
uniqu
effect
fig
inhibitori
effect
parkinmedi
mitophagi
demonstr
use
mom
protein
fig
b
matrix
protein
supplementari
materi
fig
mitochondri
marker
usp
cystein
proteas
determin
whether
effect
mitophagi
depend
enzymat
activ
gener
catalyt
inact
form
replac
activ
site
cystein
residu
posit
alanin
mutat
abolish
inhibitori
effect
parkinmedi
mitophagi
indic
effect
requir
deubiquitin
activ
fig
supplementari
materi
fig
next
use
rnaimedi
knockdown
supplementari
materi
fig
f
investig
whether
endogen
regul
mitophagi
parkintransfect
hela
cell
two
cell
model
express
endogen
parkin
human
dopaminerg
neuron
cell
primari
fibroblast
healthi
human
subject
fig
rnaimedi
reduct
protein
level
parkintransfect
hela
cell
enhanc
parkinmedi
mitophagi
induc
h
exposur
cccp
rnaimedi
knockdown
effect
fig
supplementari
materi
fig
h
interestingli
sirnamedi
knockdown
result
mitochondri
clearanc
cccp
exposur
hela
cell
lack
parkin
fig
thu
knockdown
enhanc
mitophagi
presenc
parkin
cell
cccpinduc
mitophagi
also
markedli
promot
sirnamedi
knockdown
fig
c
mitophagypromot
effect
knockdown
cell
suppress
simultan
sirnamedi
knockdown
endogen
parkin
protein
level
indic
effect
knockdown
mitophagi
parkindepend
supplementari
materi
fig
b
primari
human
fibroblast
exposur
cccp
valinomycin
h
induc
signific
mitochondri
clearanc
fig
g
howev
h
treatment
cccp
valinomycin
result
substanti
loss
mitochondria
demonstr
immunocytochem
fig
e
western
blot
fig
g
cccpand
valinomycininduc
loss
mitochondria
fibroblast
inhibit
lysosom
inhibitor
bafilomycin
confirm
autophag
natur
fig
g
mitophagi
induc
h
exposur
cccp
valinomycin
also
inhibit
rnaimedi
knockdown
indic
endogen
parkin
mediat
mitophagi
fibroblast
supplementari
materi
fig
e
interestingli
rnaimedi
knockdown
fibroblast
strongli
enhanc
mitophagi
mitophagi
alreadi
becam
demonstr
h
exposur
cccp
valinomycin
fig
cell
mitophagyenhanc
effect
knockdown
revers
simultan
knockdown
supplementari
materi
fig
g
knockdown
rescu
mitophagi
defect
mutant
pd
patient
fibroblast
demonstr
hela
cell
fig
knockdown
enhanc
mitophagi
complet
absenc
parkin
howev
mani
clinic
mutat
complet
abolish
ligas
activ
parkin
pd
patient
mutat
often
diminish
nonzero
parkin
activ
level
wonder
whether
knockdown
would
promot
parkin
function
mutant
pd
patient
cell
reduc
nonzero
parkin
activ
use
fibroblast
pd
patient
compound
heterozyg
mutat
protein
extract
control
human
fibroblast
parkin
exist
major
fulllength
speci
minor
speci
lack
ntermin
ubiquitinlik
ubl
domain
origin
intern
translat
initi
site
codon
gene
fig
fulllength
parkin
parkin
lack
ubl
domain
capabl
induc
mitophagi
mutant
cell
total
parkin
protein
level
reduc
control
level
n
complet
absenc
parkin
residu
express
ubllack
parkin
speci
gener
intern
start
site
mutant
allel
fig
contrast
control
fibroblast
mutant
fibroblast
show
littl
mitochondri
clearanc
exposur
cccp
valinomycin
h
fig
strikingli
howev
mitophagi
defect
mutant
fibroblast
rescu
knockdown
fig
rescu
revers
simultan
rnaimedi
knockdown
residu
parkin
mutant
fibroblast
supplementari
materi
fig
serinethreonin
kinas
like
parkin
link
genet
autosom
recess
pd
also
implic
mitophagi
enhanc
ligas
activ
parkin
respons
mitochondri
depolar
studi
drosophila
human
cell
reveal
overexpress
parkin
rescu
mitochondri
phenotyp
caus
defici
support
view
parkin
function
least
part
pathway
assess
whether
knockdown
also
compens
impair
function
examin
fibroblast
pd
patient
homozyg
mutat
tg
mutat
result
substitut
tryptophan
posit
glycin
residu
locat
within
kinas
domain
highli
conserv
across
speci
interestingli
fibroblast
show
reduc
mitophagi
view
antagonist
relationship
parkin
examin
rel
express
level
mous
brain
tissu
like
parkin
wide
express
across
differ
brain
region
fig
organ
fig
express
ratio
brain
among
lowest
organ
test
fig
c
immunostain
endogen
mous
primari
midbrain
cultur
reveal
strong
express
neuron
includ
dopaminerg
neuron
fig
e
endogen
neuron
predominantli
cytosol
distribut
also
partial
coloc
mitochondria
fig
could
mechan
inhibitori
effect
parkinmedi
mitophagi
consid
possibl
might
modul
parkin
function
deubiquitin
parkin
howev
found
evid
deubiquitin
parkin
basal
condit
exposur
valinomycin
fig
b
also
investig
whether
inhibit
transloc
parkin
cytosol
depolar
mitochondria
howev
effect
cccpinduc
transloc
transfect
parkin
hela
cell
fig
moreov
subcellular
fraction
western
blot
indic
prevent
cccpinduc
transloc
endogen
parkin
cell
fig
experi
also
show
substanti
portion
endogen
cell
present
mitochondriaenrich
fraction
basal
condit
fig
consist
immunocytochem
coloc
experi
neuron
fig
amount
mitochondri
fraction
increas
mitochondri
depolar
fig
determin
whether
counteract
parkinmedi
ubiquitin
depolar
mitochondria
hela
cell
transfect
parkin
hatag
ubiquitin
ubiquitin
diffus
cytosol
distribut
fig
howev
cccp
treatment
h
induc
strike
coloc
ubiquitin
mitochondria
fig
previous
report
recruit
ubiquitin
depolar
mitochondria
parkindepend
fig
importantli
overexpress
catalyt
inact
mutant
strongli
reduc
cccpinduc
cluster
ubiquitin
mitochondria
indic
oppos
parkinmedi
mitochondri
ubiquitin
fig
parkin
shown
catalyz
format
sever
distinct
type
polyubiquitin
linkag
depolar
mitochondria
includ
ubiquitin
chain
use
antibodi
specif
recogn
either
ubiquitin
chain
parkin
inde
mediat
accumul
ubiquitin
chain
mitochondria
cccp
treatment
h
fig
c
e
f
overexpress
antagon
parkinmedi
cluster
ubiquitin
chain
depolar
mitochondria
fig
c
e
f
also
examin
effect
mitochondri
ubiquitin
endogen
express
level
ubiquitin
use
subcellular
fraction
western
blot
fig
hela
cell
treat
valinomycin
h
follow
isol
mitochondri
fraction
analysi
mitochondria
immunoblot
endogen
ubiquitin
treatment
valinomycin
h
clearli
induc
parkindepend
accumul
endogen
ubiquitin
mitochondri
fraction
fig
b
strikingli
parkindepend
mitochondri
ubiquitin
strongli
potenti
rnaimedi
knockdown
fig
contrast
knockdown
effect
mitochondri
ubiquitin
fig
f
use
mitochondri
fraction
western
blot
assay
assess
ubiquitin
statu
depolar
mitochondria
control
human
fibroblast
express
endogen
parkin
supplementari
materi
fig
b
exposur
valinomycin
observ
timedepend
increas
ubiquitin
content
mitochondri
fraction
contrast
mutant
fibroblast
increas
mitochondri
ubiquitin
valinomycin
treatment
supplementari
materi
fig
b
howev
knockdown
mutant
fibroblast
result
increas
ubiquitin
mitochondria
depolar
supplementari
materi
fig
next
assess
effect
ubiquitin
statu
substrat
parkin
mom
fibroblast
fig
h
ubiquitin
also
degrad
proteasom
perform
experi
presenc
proteasom
inhibitor
knockdown
enhanc
amount
ubiquitin
endogen
respons
mitochondri
depolar
fig
h
ask
whether
parkin
also
antagonist
relationship
vivo
address
util
parkin
knockdown
drosophila
model
pd
parkindefici
fli
report
display
locomotor
defect
flight
muscl
degener
accumul
swollen
dysfunct
mitochondria
inde
rnaimedi
parkin
knockdown
fli
express
gfp
version
specif
local
mitochondria
mitogfp
result
appear
larg
clump
intens
mitogfp
signal
adult
indirect
flight
muscl
fig
c
consist
previou
work
em
analysi
reveal
vacuol
adult
flight
muscl
cell
sever
swollen
mitochondria
disrupt
crista
fig
mitochondri
membran
potenti
parkin
rnai
fli
reduc
shown
label
neuromuscular
junction
synaps
potentiometr
dye
fig
f
moreov
adult
parkin
rnai
fli
show
defect
climb
abil
line
previou
studi
fig
drosophila
genom
encod
differ
dub
drosophila
dub
bear
strongest
similar
amino
acid
sequenc
ident
similar
respect
e
valu
counteract
effect
parkin
would
expect
silenc
suppress
parkin
knockdown
phenotyp
importantli
phenotyp
inde
larg
rescu
rnaimedi
knockdown
indic
parkin
opposit
effect
fli
mitochondri
morpholog
function
vivo
fig
base
find
human
cell
propos
model
oppos
mitophagi
antagon
parkinmedi
mitochondri
ubiquitin
fig
parkinmedi
mitophagi
appear
tightli
regul
parkin
must
overcom
antagonist
effect
induc
mitochondri
clearanc
inhibitori
effect
mitophagi
remark
specif
effect
observ
close
relat
usp
recent
proteom
studi
human
cell
show
parkin
ubiquitin
site
differ
mom
protein
includ
respons
mitochondri
depolar
show
knockdown
increas
amount
ubiquitin
mitochondri
depolar
remain
investig
mitochondri
parkin
substrat
besid
deubiquin
mitochondri
ubiquitin
event
critic
induct
mitophagi
parkin
report
mediat
format
even
polyubiquitin
chain
depolar
mitochondria
show
antagon
parkinmedi
accumul
chain
mitochondria
thu
like
parkin
appear
display
strict
chaintyp
specif
observ
lack
ubiquitin
linkag
specif
consist
properti
character
member
usp
famili
also
promiscu
abil
hydrolyz
multipl
ubiquitin
linkag
type
model
antagonist
control
mitochondri
fate
parkin
support
vivo
find
parkin
rnai
drosophila
model
pd
knockdown
closest
homolog
fli
larg
rescu
mitochondri
defect
parkin
rnai
fli
although
cellular
mechan
underli
mitochondri
abnorm
parkindefici
fli
fulli
delin
impair
mitophagi
probabl
contribut
phenotyp
inhibit
mitophagi
fli
similar
human
cell
suppress
level
would
allow
residu
parkin
parkin
rnai
fli
target
damag
mitochondria
remov
parkin
regul
mitochondri
homeostasi
also
pathway
unrel
mom
protein
ubiquitin
mitophagi
exampl
parkinmedi
ubiquitin
control
level
pari
transcript
repressor
regul
mitochondri
biogenesi
also
parkin
promot
lubacmedi
ubiquitin
nemo
therebi
induc
transcript
upregul
mitochondri
gtpase
involv
control
crista
structur
inner
membran
fusion
apoptosi
futur
work
address
whether
also
affect
pathway
previous
shown
activ
tgfb
pathway
deubiquitin
type
tgfb
receptor
receptoractiv
smad
protein
enhanc
tgfb
signal
promot
oncogenesi
gene
amplif
elev
activ
found
glioblastoma
sever
human
malign
whether
parkin
also
affect
tgfb
pathway
current
unknown
intriguingli
consider
evid
suggest
parkin
tumor
suppressor
although
mechan
effect
well
understood
somat
inactiv
mutat
diminish
parkin
level
report
glioblastoma
human
cancer
thu
antagonist
relationship
parkin
may
relev
mitophagi
pd
also
oncogenesi
usp
druggabl
target
illustr
recent
develop
select
smallmolecul
inhibitor
import
implic
data
inhibit
may
therapeut
potenti
pd
case
caus
reduc
parkin
level
diminish
parkin
activ
pd
result
mutat
probabl
also
occur
sporad
form
pd
activ
parkin
becom
progress
deplet
age
human
brain
due
oxid
nitros
dopaminerg
damag
pd
case
diminish
nonzero
parkin
activ
inhibit
could
enabl
residu
parkin
exert
neuroprotect
function
effect
follow
primari
antibodi
use
immunofluoresc
construct
encod
untag
wildtyp
human
parkin
parkin
ntermin
flag
tag
hatag
ubiquitin
describ
previous
entri
vector
contain
cdna
human
ctermin
mycflag
tag
purchas
origen
mutant
construct
gener
use
quikchang
lightn
sitedirect
mutagenesi
kit
agil
technolog
use
sens
primer
cctaagtaa
cttgggaaatacggctttcatgaactcagctattca
antisens
primer
ctgaatagctgagttcat
mutagenesi
verifi
sequenc
cdna
encod
myctag
form
gift
dr
pj
lehner
sirna
target
human
invitrogen
hela
cell
grown
transfect
cdna
sirna
describ
primari
embryon
mous
midbrain
neuron
cultur
describ
immunostain
day
vitro
human
dermal
fibroblast
obtain
skin
biopsi
medial
aspect
upper
limb
written
inform
consent
procedur
approv
local
ethic
committe
control
healthi
male
born
control
healthi
femal
born
control
healthi
male
born
control
healthi
femal
born
clinic
histori
pd
patient
compound
heterozyg
mutat
femal
born
publish
patient
mutat
femal
born
develop
earlyonset
pd
age
present
initi
rightsid
arm
leg
tremor
bradykinesia
rigid
respond
well
levodopa
diseas
progress
develop
motor
fluctuat
twenti
year
diseas
onset
requir
bilater
pallidotomi
treat
sever
dyskinesia
eldest
seven
children
born
consanguin
parent
one
sister
develop
pd
age
year
twin
brother
sister
die
earli
childhood
anoth
sister
two
brother
remain
unaffect
mutat
identifi
dna
extract
blood
use
jet
quick
spin
column
accord
manufactur
instruct
astral
scientif
australia
purifi
dna
subject
pcr
cycl
incorpor
dye
label
termin
appli
biosystem
australia
pcr
condit
detail
cycl
min
pcr
reaction
clean
final
reaction
sampl
sequenc
use
abi
capillari
sequenc
appli
biosystem
australia
human
fibroblast
grown
dmem
invitrogen
supplement
fetal
bovin
serum
greiner
bioon
nonessenti
amino
acid
penicillin
uml
streptomycin
mg
ml
sodium
bicarbon
co
humidifi
atmospher
human
fibroblast
transfect
nm
sirna
use
neon
transfect
system
invitrogen
accord
manufactur
instruct
cccp
calbiochem
valinomycin
sigma
bafilomycin
sigma
dmso
ad
h
transfect
immunostain
cultur
cell
perform
describ
experi
measur
effect
parkin
myctag
dub
coloc
hatag
ubiquitin
mitochondria
quadrupl
immunofluoresc
perform
use
mous
antiparkin
chicken
antimyc
rabbit
antiha
sheep
anticytochrom
c
primari
antibodi
donkey
secondari
antibodi
antimous
alexa
antichicken
dylight
antirabbit
antisheep
alexa
nuclei
stain
iodid
mm
secondari
antibodi
solut
invitrogen
confoc
imag
mm
slice
thick
acquir
room
temperatur
either
axioskop
microscop
meta
carl
zeiss
na
oil
plan
apochromat
object
axiocam
hr
camera
carl
zeiss
analysi
quadrupl
immunostain
nikon
eclips
microscop
equip
biorad
radianc
laser
scan
hardwar
na
oil
plan
apochromat
object
bright
contrast
adjust
nih
imagej
softwar
transloc
mitophagi
ubiquitin
experi
random
imag
captur
analyz
investig
blind
experiment
condit
minimum
cell
per
condit
analyz
per
experi
coloc
assess
line
scan
analysi
distanc
mm
use
plot
profil
function
imagej
coimmunoprecipit
perform
describ
brief
hela
cell
wash
icecold
pb
remov
scraper
resuspend
lysi
buffer
mm
trishcl
triton
ph
solubil
min
insolubl
materi
remov
centrifug
min
protein
concentr
determin
use
biorad
protein
assay
equal
protein
amount
incub
antiflag
affin
gel
sigma
h
wash
three
time
lysi
buffer
bound
protein
elut
lysi
buffer
contain
flag
peptid
mg
ml
sigma
min
follow
sd
page
blot
onto
pvdf
membran
incub
block
solut
primari
secondari
antibodi
immunoreact
visual
ecl
pierc
ecl
prime
ge
healthcar
amersham
hyperfilm
ecl
ge
healthcar
fujifilm
imag
densiti
scan
signal
measur
unscanit
gel
silk
scientif
mitochondria
isol
describ
minor
modif
cell
harvest
scraper
wash
pb
homogen
glass
pestl
isol
medium
mm
sucros
mm
edta
mm
tri
mop
ph
nuclei
undisrupt
cell
remov
centrifug
min
supernat
centrifug
min
result
supernat
contain
cytosol
separ
pellet
pellet
resuspend
isol
medium
centrifug
min
step
repeat
three
time
final
pellet
enrich
mitochondria
analyz
sd
page
western
blot
experi
assay
mitochondri
ubiquitin
nethylmaleimid
mm
sigma
ad
isol
medium
prevent
deubiquitin
mitochondria
cell
lysi
ubiquitin
parkin
assay
describ
one
day
transfect
hela
cell
flagparkin
haubiquitin
protein
extract
denatur
lysi
buffer
mm
trishcl
ph
mm
edta
sd
uml
dnase
proteas
inhibitor
cocktail
roch
dissoci
parkin
bind
partner
boil
min
extract
dilut
nondenatur
lysi
buffer
mm
tri
hcl
ph
mm
nacl
mm
edta
triton
proteas
inhibitor
cocktail
follow
antiflag
immunoprecipit
describ
western
blot
fli
kept
standard
cornmeal
molass
medium
parkin
transgen
uasrnai
line
obtain
vienna
stock
center
vdrc
express
use
w
w
control
use
w
w
w
uasmitogfp
obtain
bloomington
stock
center
indiana
usa
quantifi
parkin
mrna
level
rna
isol
adult
thorac
realtim
rtpcr
perform
previous
describ
use
primer
ccagcaatgtcaccat
parkin
ttctttggt
data
normal
use
ribosom
gene
realtim
pcr
show
parkin
mrna
level
parkin
rnai
line
control
parkin
level
n
mrna
level
rnai
line
control
level
n
fluoresc
imag
mitogfp
adult
thorax
muscl
adult
fli
fix
pb
formaldehyd
triton
h
fixat
dissect
thorac
mount
vectashield
vector
laboratori
imag
zeiss
lsm
meta
confoc
microscop
use
oil
na
object
mitogfp
imag
use
nm
laser
band
pass
emiss
filter
number
mitochondri
clump
determin
autom
manner
use
analyz
particl
plugin
nih
imagej
softwar
follow
set
size
mm
circular
mitochondri
clump
size
analyz
follow
set
size
mm
circular
electron
microscopi
adult
fli
thorac
first
fix
paraformaldehydeglutaraldehyd
postfix
osmium
tetroxid
final
dehydr
embed
epon
describ
tem
analysi
differ
section
nm
thick
stain
uranyl
acet
lead
citrat
dissect
third
instar
drosophila
larva
incub
min
mm
molecular
probe
solut
wash
min
solut
imag
mitochondria
neuromuscular
junction
muscl
segment
imag
use
follow
filter
semrock
green
red
emiss
respect
ex
nm
em
nm
dichroic
nm
ex
nm
em
nm
dichroic
nm
mitochondria
neuromuscular
bouton
easili
distinguish
shape
morpholog
green
label
label
bouton
differ
muscl
cell
imag
captur
nikon
microscop
na
water
immers
object
data
analyz
nisel
nikon
measur
ratio
red
green
fluoresc
ten
fli
per
batch
load
empti
vial
cm
diamet
cm
height
number
fli
cross
cm
line
tap
fli
count
assay
perform
batch
fli
signific
differ
analyz
twotail
student
ttest
comparison
two
group
oneway
anova
post
hoc
holm
sidak
test
comparison
two
group
sigmastat
systat
valu
error
bar
repres
meansem
ncbi
blast
blastp
use
search
homolog
determin
e
valu
amino
acid
sequenc
ident
similar
supplementari
materi
avail
hmg
onlin
